| Identification | Back Directory | [Name]
NS-1209 | [CAS]
205645-02-9 | [Synonyms]
NS-1209
SPD-502, NS-1209
2-[[[5-[4-[(Dimethylamino)sulfonyl]phenyl]-1,2,6,7,8,9-hexahydro-8-methyl-2-oxo-3H-pyrrolo[3,2-h]isoquinolin-3-ylidene]amino]oxy]-4-hydroxybutanoic acid monosodium salt | [Molecular Formula]
C24H27N4NaO7S | [MOL File]
205645-02-9.mol | [Molecular Weight]
538.549 |
| Hazard Information | Back Directory | [Uses]
SPD-502 sodium is a novel glutamate antagonist with potential neuroprotective properties, particularly in brain ischemia. It selectively targets the AMPA receptor, showing high affinity (IC50 = 0.043 μM) and competitive inhibition of AMPA-induced effects in rat cortical membranes and cultured mouse cortical neurons. In vivo, SPD-502 sodium effectively blocks AMPA-evoked spike activity in the hippocampus after intravenous administration, significantly increasing the seizure threshold in mice and demonstrating robust protection against ischemia-induced damage to hippocampal neurons in gerbils. These findings suggest SPD-502 sodium may be promising for treating neurodegenerative conditions associated with glutamate excitotoxicity[1]. | [References]
[1] SPD-502: A Water-Soluble and In Vivo Long-Lasting Ampa Antagonist with Neuroprotective Activity |
|
|